{
  "@context": "aku-v2",
  "@type": "definition",
  "@id": "health-sciences:medicine:neurology:neuro-013",
  "metadata": {
    "version": "1.0.0",
    "created": "2026-01-09T01:54:58.000Z",
    "contributors": [
      "copilot-agent"
    ],
    "confidence": 0.9,
    "status": "validated"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/neurology",
    "type": "definition",
    "difficulty": "intermediate",
    "importance": "high"
  },
  "content": {
    "title": "Myasthenia Gravis",
    "summary": "Neuromuscular junction disorder",
    "key_points": [
      "Fatigable weakness",
      "AChR antibodies",
      "Pyridostigmine, immunotherapy"
    ]
  },
  "prerequisites": [],
  "related_concepts": [],
  "evidence": {
    "citations": [],
    "confidence_rationale": "Standard medical knowledge"
  },
  "learning_objectives": [
    "Understand Myasthenia Gravis"
  ],
  "clinical_pearls": [
    "Fatigable weakness"
  ]
}